(Reuters) – The European Medicines Agency (EMA), eager to accelerate access to promising new drugs, may be getting too cozy with the pharmaceutical companies it regulates.
That is the concern of the watchdog charged with overseeing administrative irregularities in the European Union, which is launching a strategic inquiry to see if early-stage interactions with firms could influence agency approval decisions.
Get the full story at our sister site, Drug Delivery Business News.
The post EU watchdog: EU drug agency may be too cozy with industry appeared first on MassDevice.